Direct anti-metastatic efficacy by the DNA enzyme Dz13 and downregulated MMP-2, MMP-9 and MT1-MMP in tumours

Cancer Cell International

Volumn 10, Issue , 2010, Pages

  Tan, Mei L ^a,b   Choong, Peter F M ^a,b,c   Dass, Crispin R ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBOZYME; DNA ENZYME DZ13; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 14; PROTEIN C JUN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG DETERMINATION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; OSTEOSARCOMA; PROSTATE CANCER;

EID: 77952298658     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-10-9     Document Type: Article

References (44)

1. Khachigian LM, Fahmy RG, Zhang G, Bobryshev YV, Kaniaros A. c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury. Inhibition by a novel DNA enzyme targeting c-Jun. J Biol Chem 2002, 277:22985-22991. 10.1074/jbc.M200977200, 11891228.
2. Tan ML, Choong PF, Dass CR. DNAzyme delivery systems: getting past first base. Expert Opin Drug Deliv 2009, 6:127-138. 10.1517/17425240902751605, 19239385.
3. Zhang G, Dass CR, Sumithran E, Di Girolamo N, Sun LQ, Khachigian LM. Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst 2004, 96:683-696.
4. Zhang G, Luo X, Sumithran E, Pua VS, Barnetson RS, Halliday GM, Khachigian LM. Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression. Oncogene 2006, 25:7260-7266. 10.1038/sj.onc.1209726, 16785994.
5. Dass CR, Friedhuber AM, Khachigian LM, Dunstan DE, Choong PF. Downregulation of c-jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic model. Cancer Biol Ther 2008, 7:1033-1036. 10.1158/1535-7163.MCT-07-0179, 18414033.
6. Dass CR, Khachigian LM, Choong PF. c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Mol Cancer Ther 2008, 7:1909-1912. 10.1158/1535-7163.MCT-08-0086, 18645001.
7. Dass CR, Galloway SJ, Clark JC, Khachigian LM, Choong PF. Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy. Cancer Biol Ther 2008, 7:1297-1301. 10.1158/1535-7163.MCT-07-2267, 18497564.
8. Dass CR, Khachigian LM, Choong PFM. c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Mol Cancer Res 2008, 7:1909-1912.
9. Dass CR, Friedhuber AM, Khachigian LM, Dunstan DE, Choong PF. Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activity. J Microencaps 2008, 25:421-425.
10. Pillay V, Dass CR, Choong PF. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 2007, 25:33-39. 10.1016/j.tibtech.2006.10.011, 17084931.
11. Friedl P, Wolf K. Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res 2008, 68:7247-7249. 10.1158/0008-5472.CAN-08-0784, 18794108.
12. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol 2004, 50:87-100. 10.1016/j.critrevonc.2003.09.001, 15157658.
13. Itoh Y. MT1-MMP: a key regulator of cell migration in tissue. IUBMB Life 2006, 58:589-596. 10.1080/15216540600962818, 17050376.
14. Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruiter DJ, van Muijen GN. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol 2000, 191:245-256. 10.1002/1096-9896(2000)9999:9999<::AID-PATH632>3.0.CO;2-#, 10878545.
15. Crispi S, Calogero RA, Santini M, Mellone P, Vincenzi B, Citro G, Vicidomini G, Fasano S, Meccariello R, Cobellis G, Menegozzo S, Pierantoni R, Facciolo F, Baldi A, Menegozzo M. Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS One 2009, 4:e7016. 10.1371/journal.pone.0007016, 2737627, 19753302.
16. Banerji A, Chakraborti J, Mitra A, Chatterjee A. Cell membrane-associated MT1-MMP-dependent activation of pro-MMP-2 in A375 melanoma cells. J Environ Pathol Toxicol Oncol 2005, 24:3-17. 10.1615/JEnvPathToxOncol.v24.i1.20, 15715505.
17. Han YP, Yan C, Zhou L, Qin L, Qin L, Tsukamoto H. A matrix metalloproteinase-9 activation cascade by hepatic stellate cells in trans-differentiation in the three-dimensional extracellular matrix. J Biol Chem 2007, 282:12928-12939. 10.1074/jbc.M700554200, 2376818, 17322299.
18. Shou Y, Hirano T, Gong Y, Kato Y, Yoshida K, Ohira T, Ikeda N, Konaka C, Ebihara Y, Zhao F, Kato H. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer 2001, 85:1706-1712. 10.1054/bjoc.2001.2137, 2363988, 11742492.
19. Ria R, Loverro G, Vacca A, Ribatti D, Cormio G, Roccaro AM, Selvaggi L. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 agree with progression of ovarian endometriomas. Eur J Clin Invest 2002, 32:199-206. 10.1046/j.1365-2362.2002.00960.x, 11895472.
20. Mönig SP, Baldus SE, Hennecken JK, Spiecker DB, Grass G, Schneider PM, Thiele J, Dienes HP, Hölscher AH. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2001, 39:597-602. 10.1046/j.1365-2559.2001.01306.x, 11903578.
21. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999, 274:13066-13076. 10.1074/jbc.274.19.13066, 10224058.
22. Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN, Han L, Gershenson DM, Sood AK. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 2006, 12:1707-1714. 10.1158/1078-0432.CCR-05-2338, 16551853.
23. Ishimaru H, Kageyama Y, Hayashi T, Nemoto T, Eishi Y, Kihara K. Expression of matrix metalloproteinase-9 and bombesin/gastrin-releasing peptide in human prostate cancers and their lymph node metastases. Acta Oncol 2002, 41:289-296. 10.1080/02841860260088845, 12195749.
24. Monier F, Mollier S, Guillot M, Rambeaud JJ, Morel F, Zaoui P. Urinary release of 72 and 92 kDa gelatinases, TIMPs, N-GAL and conventional prognostic factors in urothelial carcinomas. Eur Urol 2002, 42:356-363. 10.1016/S0302-2838(02)00350-0, 12361901.
25. Dass CR, Saravolac EG, Li Y, Sun L-Q. Cellular uptake, distribution and stability of 10-23 deoxyribozymes. Antisense Nucl Acid Drug Dev 2002, 12:289-299.
26. Ek ET, Dass CR, Contreras KG, Choong PF. Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis. Cancer Gene Ther 2007, 14:616-626. 10.1038/sj.cgt.7701044, 17479108.
27. Ek ET, Dass CR, Contreras KG, Choong PF. Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor. Clin Exp Metastasis 2007, 24:93-106. 10.1007/s10585-007-9062-1, 17458711.
28. Dass CR, Ek ET, Contreras KG, Choong PF. A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clin Exp Metastasis 2006, 23:367-380. 10.1007/s10585-006-9046-6, 17187230.
29. Dass CR, Choong PF. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol Cancer Ther 2007, 6:3263-3270. 10.1158/1535-7163.MCT-07-0546, 18089720.
30. Ek ET, Dass CR, Contreras KG, Choong PF. PEDF-derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma. J Orthop Res 2007, 25:1671-1680. 10.1002/jor.20434, 17600821.
31. Fahmy RG, Dass CR, Sun L-Q, Chesterman CN, Khachigian LM. Early Growth Response factor-1: A key mediator of tumour angiogenesis and neovascularisation. Nat Med 2003, 9:1026-1032. 10.1038/nm905, 12872165.
32. Mitchell A, Dass CR, Sun LQ, Khachigian LM. Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumour growth by DNAzymes targeting the zinc finger transcription factor EGR-1. Nucleic Acids Res 2004, 32:3065-3069. 10.1093/nar/gkh626, 434432, 15181171.
33. Tan ML, Choong PF, Dass CR. Osteosarcoma: Conventional treatment vs. gene therapy. Cancer Biol Ther 2009, 8:106-117.
34. Peng TL, Chen J, Mao W, Song X, Chen MH. Aryl hydrocarbon receptor pathway activation enhances gastric cancer cell invasiveness likely through a c-Jun-dependent induction of matrix metalloproteinase-9. BMC Cell Biol 2009, 10:27. (PMID: 19371443), 10.1186/1471-2121-10-27, 2680824, 19371443.
35. Mackay AR, Ballin M, Pelina MD, Farina AR, Nason AM, Hartzler JL, Thorgeirsson UP. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis 1992, 12:168-184.
36. Morozevich G, Kozlova N, Cheglakov I, Ushakova N, Berman A. Integrin alpha5beta1 controls invasion of human breast carcinoma cells by direct and indirect modulation of MMP-2 collagenase activity. Cell Cycle 2009, 8:2219-2225.
37. Fromigué O, Hamidouche Z, Marie PJ. Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem 2008, 283:30549-30556. 10.1074/jbc.M801436200, 2662148, 18757369.
38. Haas TL, Doyle JL, Distasi MR, Norton LE, Sheridan KM, Unthank JL. Involvement of MMPs in the outward remodeling of collateral mesenteric arteries. Am J Physiol Heart Circ Physiol 2007, 293:H2429-H2437. 10.1152/ajpheart.00100.2007, 17644578.
39. Pereira AM, Strasberg-Rieber M, Rieber M. Invasion-associated MMP-2 and MMP-9 are up-regulated intracellularly in concert with apoptosis linked to melanoma cell detachment. Clin Exp Metastasis 2005, 22:285-295. 10.1007/s10585-005-8672-8, 16170665.
40. Dass CR, Choong PF. C-jun: pharmaceutical target for DNAzyme therapy of multiple pathologies. Pharmazie 2008, 63:411-414.
41. Hosoi M, Yoshioka M, Tanaka Y, Wada I, Nakao M, Maeda S, Onda M. Primary osteogenic sarcoma of the breast. Report of a case. Nippon Geka Gakkai Zasshi 1989, 90:1262-1265.
42. Hihara T, Tanaka M, Inatsuchi H, Katsuoka Y, Katsuoka Y, Kawamura N. Primary osteosarcoma of the bladder: a case report. Hinyokika Kiyo 1992, 38:849-852.
43. Luu HH, Kang Q, Park JK, Si W, Luo Q, Jiang W, Yin H, Montag AG, Simon MA, Peabody TD, Haydon RC, Rinker-Schaeffer CW, He TC. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis 2005, 22:319-329. 10.1007/s10585-005-0365-9, 16170668.
44. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008, 134:281-297. 10.1007/s00432-007-0330-x, 17965883.